Seres Therapeutics Ownership
| 1S9 Stock | EUR 0.83 0.05 5.68% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Seres |
Seres Stock Ownership Analysis
About 86.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 2.18. Seres Therapeutics had not issued any dividends in recent years. Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. SERES THERAPEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 155 people. For more info on Seres Therapeutics please contact Eric Shaff at 617 945 9626 or go to https://www.serestherapeutics.com.Seres Therapeutics Outstanding Bonds
Seres Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Seres Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Seres bonds can be classified according to their maturity, which is the date when Seres Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.